Results 21 to 30 of about 2,912 (169)

Antimicrobial activities of ceftazidime/avibactam, ceftolozane/tazobactam, imipenem/relebactam, meropenem/vaborbactam, and comparators against Pseudomonas aeruginosa from patients with skin and soft tissue infections

International Journal of Infectious Diseases, 2021
Background: The limited armamentarium against multidrug-resistant Gram-negative bacilli led to the development of a new generation of β-lactam/β-lactamase inhibitor combinations (BL/BLI).
Helio S. Sader, Mariana Castanheira, Leonard R. Duncan, Rodrigo E. Mendes   +3 more
doaj   +1 more source

New evidence in severe pneumonia: meropenem-vaborbactam

Revista Española de Quimioterapia, 2022
The appearance and spread of new mechanisms of bacterial resistance to antibiotics is a serious health problem. One of the most difficult resistance mechanisms to treat is the production of carbapenemases. Carbapenemase KPC is one of those mechanisms with few therapeutic options.
Forteza Guillot, Maria, Martin Cerezuela, Maria, Ramirez, Paula   +2 more
openaire   +3 more sources

The European Medicines Agency Approved the New Antibacterial Drugs – Response to the 2017 Who Report on the Global Problem of Multi-Drug Resistance

Postępy Mikrobiologii, 2021
The growing problem of antimicrobial resistance has been classified by the World Health Organization (WHO) as one of the top ten threats to mankind. In a special report published in 2017, the WHO presented a list of microorganisms for which the search ...
Krajewska Joanna, Laudy Agnieszka Ewa
doaj   +1 more source

A Post-Neurosurgical Infection due to KPC-Producing Klebsiella pneumoniae Treated with Meropenem-Vaborbactam: A Case Report

International Journal of Infectious Diseases, 2022
This case report describes a patient with post-neurosurgical infection and bacteremia caused by Klebsiella pneumoniae carbapenemase-producing Klebsiella pneumoniae.
Seohyun Choi, Marianna Fedorenko, Janet Lin-Torre, Nirav Mistry, Steven Smoke   +4 more
doaj   +1 more source

Stability Studies of Antipseudomonal Beta Lactam Agents for Outpatient Therapy

Pharmaceutics, 2023
Outpatient parenteral antimicrobial therapy (OPAT) is a useful treatment strategy against Pseudomonas aeruginosa and other multidrug-resistant bacteria.
Beatriz Fernández-Rubio, Laura Herrera-Hidalgo, Arístides de Alarcón, Rafael Luque-Márquez, Luis E. López-Cortés, Sònia Luque, José María Gutiérrez-Urbón, Aurora Fernández-Polo, Alicia Gutiérrez-Valencia, María V. Gil-Navarro   +9 more
doaj   +1 more source

Effect and Safety of Meropenem–Vaborbactam versus Best-Available Therapy in Patients with Carbapenem-Resistant Enterobacteriaceae Infections: The TANGO II Randomized Clinical Trial

Infectious Diseases and Therapy, 2018
Introduction Treatment options for carbapenem-resistant Enterobacteriaceae (CRE) infections are limited and CRE infections remain associated with high clinical failure and mortality rates, particularly in vulnerable patient populations.
Richard G. Wunderink, Evangelos J. Giamarellos-Bourboulis, Galia Rahav, Amy J. Mathers, Matteo Bassetti, Jose Vazquez, Oliver A. Cornely, Joseph Solomkin, Tanaya Bhowmick, Jihad Bishara, George L. Daikos, Tim Felton, Maria Jose Lopez Furst, Eun Jeong Kwak, Francesco Menichetti, Ilana Oren, Elizabeth L. Alexander, David Griffith, Olga Lomovskaya, Jeffery Loutit, Shu Zhang, Michael N. Dudley, Keith S. Kaye   +22 more
doaj   +1 more source

Ceftazidime/Avibactam, Meropenem/Vaborbactam, or Both? Clinical and Formulary Considerations [PDF]

Clinical Infectious Diseases, 2018
Ceftazidime/avibactam and meropenem/vaborbactam are changing the management of invasive infections due to carbapenem-resistant Enterobacteriaceae (CRE), leading to higher rates of clinical cure, decreased mortality, and decreased rates of acute kidney injury compared with colistin-based regimens.
Jason M, Pogue, Robert A, Bonomo, Keith S, Kaye   +2 more
openaire   +2 more sources

Evaluation with E-test of the meropenem/vaborbactam association in carbapenem-resistant and sensitive negative control strains isolates of samples processed at the Laboratory of the Rivoli Hospital

Microbiologia Medica, 2022
Background and aims: Meropenem (Mer) and vaborbactam (Vab) is a combination of a carbapenem and a new β-lactamase inhibitor used in adults to treat different types of infections caused by Gram-negative bacteria.
Giuseppina Amarù, Lara Scoppapietra, Cristina Crocillà, Marika Salafia, Mara Finotti, Vittorio Schiavo, Valentino Granero   +6 more
doaj   +1 more source

Pharmacokinetic/Pharmacodynamic Adequacy of Novel β-Lactam/β-Lactamase Inhibitors against Gram-Negative Bacterial in Critically Ill Patients

Antibiotics, 2021
The optimal regimens of novel β-lactam/β-lactamase inhibitors (BLBLIs), ceftazidime/avibactam, ceftolozane/tazobactam, and meropenem/vaborbactam, are not well defined in critically ill patients.
Ruiying Han, Dan Sun, Sihan Li, Jiaojiao Chen, Mengmeng Teng, Bo Yang, Yalin Dong, Taotao Wang   +7 more
doaj   +1 more source

QPX7728, An Ultra-Broad-Spectrum B-Lactamase Inhibitor for Intravenous and Oral Therapy: Overview of Biochemical and Microbiological Characteristics

Frontiers in Microbiology, 2021
QPX7728 is a novel β-lactamase inhibitor (BLI) that belongs to a class of cyclic boronates. The first member of this class, vaborbactam, is a BLI in the recently approved Vabomere (meropenem-vaborbactam).
Olga Lomovskaya, Ruslan Tsivkovski, Dongxu Sun, Raja Reddy, Maxim Totrov, Scott Hecker, David Griffith, Jeffery Loutit, Michael Dudley   +8 more
doaj   +1 more source